Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Huddinge – page 2

218 clinical trials in Huddinge, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Huddinge at a glance
218
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

218 trials in Huddinge

Open in trial search

Plasma cell myeloma refractory

Recruiting

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Janssen Cilag International

Cholangitis sclerosing

Recruiting

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Acute myeloid leukaemia

Recruiting

A study of hydroxyurea added to standard drug combination to assess safety and effectiveness in adults with relapsed or refractory acute myeloid leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Karolinska University Hospital

Pancreatic carcinoma metastatic

Recruiting

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Revolution Medicines Inc.

Plasma cell myeloma

Recruiting

A Study to Assess Safety and Efficacy of Surzetoclax Alone or with Etentamig in Adults with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Etentamig
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Alpha-1 antitrypsin deficiency

Recruiting

Safety and Efficacy of TSRA-196 (rnaivt9315 and rnacs24757) in Adults with Lung or Liver Disease due to Alpha‑1 Antitrypsin Deficiency

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years

Kidney transplant rejection

Recruiting

Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Immunoglobulin G4 related disease

Recruiting

A study to evaluate the efficacy and safety of rilzabrutinib in adults with active IgG4-related disease

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colorectal cancer stage III

Recruiting

Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Unicancer

Secondary progressive multiple sclerosis

Recruiting

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Therapy cessation

Recruiting

Study of the effects of stopping elranatamab and teclistamab treatment in patients with multiple myeloma who have had a significant response to therapy.

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Vaestra Goetalandsregionen

Amyotrophic lateral sclerosis

Recruiting

A Study Testing the Safety of LTX-002 Sodium Given into the Spinal Canal in Adults with Amyotrophic Lateral Sclerosis

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:LTX-002 sodium
  • Sponsor:Leal Therapeutics Inc.

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Huddinge

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies exploring treatments for heart failure prevention and cardiovascular disease, including investigations into cholesterol metabolism and blood pressure management.

  • PCSK9 inhibitors and statins research
  • Heart failure prevention trials
  • Lipoprotein management studies

Comprehensive research focusing on reducing cardiovascular events and improving patient outcomes.

02 Oncology Studies

Groundbreaking research in blood cancers, including acute myeloid leukemia and multiple myeloma, with innovative therapeutic approaches.

  • Advanced breast cancer treatments
  • Leukemia therapy combinations
  • CAR T Cell therapy trials

Studies evaluating novel treatment combinations and targeted therapies for various cancer types.

03 Neurological Disorders

Clinical investigations focusing on Alzheimer's disease and amyotrophic lateral sclerosis, exploring innovative therapeutic approaches.

  • Cognitive impairment treatments
  • ALS survival studies
  • Inflammatory response research

Studies examining new therapeutic options for progressive neurological conditions.

04 Chronic Conditions

Research initiatives addressing chronic kidney disease, cystic fibrosis, and other long-term health conditions.

  • Kidney disease management
  • Diabetes treatment studies
  • Organ transplant research

Comprehensive studies aimed at improving quality of life for patients with chronic conditions.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.